28 September 2026, Melbourne Integral Diagnostics Limited (ASX: IDX) will hold its 202 6 Annual General Meeting on October 202 6 at 10:00am (Melbourne Time). Thursday , 29 Shareholders are able to participate in the AGM in person or online: In…
28 September 2026, Melbourne
Integral Diagnostics Limited
(ASX: IDX) will hold its 202 6 Annual General Meeting on
October 202 6 at 10:00am (Melbourne Time).
Thursday , 29
Shareholders are able to participate in the AGM in person or online:
In person:
At the offices of Herbert Smith Freehills Kramer, Level 24, 80 Collins Street, Melbourne
VIC.
Online:
Computershare Meeting Platform at
http://meetnow.global/MP47PKC
instructions set out in the Notice of Annual General Meeting.
using the
In accordance with ASX Listing Rule 3.17.1, the following documents are attached:
•
Notice and Access Letter;
•
Notice of Annual General Meeting;
•
Proxy Voting Form; and
•
Online Meeting Guide.
For further details contact
Integral Diagnostics
John Merity
Company Secretary
Tel: 0418 817 255
Email: [email protected]
Authorised for lodgement by the
Company Secretary .
About IDX:
Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand. IDX
employs some of Australasia’s leading radiologists and diagnostic imaging specialists in a unique medical
leadership model that ensures quali ty patient care, service and access. Good medicine is good business. For more
information, please visit www.integraldiagnostics.com.au/
Need assistance?
Phone:
1300 850 505 (within Australia)
+61 3 9415 4000 (outside Australia)
Online:
www.investorcentre.com/contact
L000001
IDX
MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030
Integral Diagnostics Limited Annual General Meeting
The Integral Diagnostics Limited Annual General Meeting will be held on Thursday, 29 October 2026 at
10:00am (Melbourne time). You are encouraged to participate in the meeting using the following options:
ACCESS THE NOTICE OF MEETING AND MAKE YOUR VOTE COUNT
To access the Notice of Meeting and other meeting documentation, and to lodge a proxy, visit
www.investorvote.com.au and use the below information:
Control Number: 999999
SRN/HIN: I9999999999
PIN: 99999
For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com
For your proxy appointment to be effective it must be received by 10:00am (Melbourne time)
Tuesday, 27 October 2026.
ATTENDING THE MEETING VIRTUALLY
To watch the webcast, ask questions and vote on the day of the meeting, please visit:
http://meetnow.global/MP47PKC
For instructions refer to the online user guide www.computershare.com.au/virtualmeetingguide
ATTENDING THE MEETING IN PERSON
The meeting will be held at:
The offices of Herbert Smith Freehills Kramer, Level 24, 80 Collins Street, Melbourne, Victoria
You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form
and may elect not to receive annual reports. To do so, contact Computershare.
Samples/000001/000001
Notice of
Annual General
Meeting
2026
INVITATION TO SHAREHOLDERS
Dear Fellow Shareholder,
On behalf of Integral Diagnostics Limited (Company or IDX), I am pleased to invite you to IDX’s 2026 Annual General Meeting (AGM or
Meeting). The AGM is an important part of the IDX calendar and we encourage you to read these materials and attend the meeting.
This year’s AGM will be held on Thursday, 29 October 2026 commencing at at 10.00am (Melbourne time) at the offices of Herbert Smith
Freehills Kramer, Level 24, 80 Collins Street, Melbourne, Victoria.
Shareholders who cannot attend in person can participate in the meeting online using a smartphone, tablet, or computer at: http://
meetnow.global/MP47PKC. Further details on how to participate online are set out at page 15 of this Notice of Meeting.
In this Notice of Meeting are:
Items of Business (page 03)
Explanatory Memorandum (page 05)
Important Information regarding the AGM (page 15)
••
•
Your personalised proxy form is also enclosed with this Notice.
There are a number of items of business on the 2026 AGM agenda and the Board, excluding interested Directors where relevant,
recommends that shareholders vote in favour of the proposed resolutions.
Shareholders are encouraged to lodge a direct vote or directed proxy in advance of the AGM. If you wish to lodge a direct vote or
appoint a proxy, you can do so before 10.00am (Melbourne time) on Tuesday, 27 October 2026. Further details on how to submit or
return your proxy form are set out on page 16 and in the proxy form.
Shareholders are also encouraged to submit written questions by email or online in advance of the AGM before 5:00pm (Melbourne
time) on Thursday, 22 October 2026. Please note that individual responses will not be sent to shareholders.
If you are able to attend in person, you will need to register on arrival. Registration will open from 9.00am. Following the meeting, you
are welcome to join the Board and our senior management team for light refreshments.
I look forward to welcoming you to our AGM.
Toby Hall
Chair
25 September 2026
02
ITEMS OF BUSINESS
Important information on each item of business is set out in the
Explanatory Memorandum which accompanies and forms part of
this Notice.
-
DISCUSSION OF FINANCIAL STATEMENTS
AND REPORTS
To discuss the Financial Report, Directors' Report, Sustainability
Report and Auditor's Reports for the year ended 30 June 2026.
-
REMUNERATION REPORT
To consider and, if thought appropriate, pass the following
resolution as a non-binding ordinary resolution:
"That the Remuneration Report for the year ended 30 June 2026
be adopted."
Note: Voting exclusions apply to this item of business. Please see
page 17 for further details.
- RE-ELECTION OF MR TOBY HALL AS
A DIRECTOR
To consider and, if thought appropriate, pass the following
resolution as an ordinary resolution:
"That Mr Toby Hall, being eligible, be re-elected as a Director."
Details of the qualifications and experience of Mr Hall are set out
in the Explanatory Memorandum.
-
RE-ELECTION OF MS INGRID PLAYER AS
A DIRECTOR
-
APPROVAL OF EQUITY GRANTS TO THE CEO
To consider and, if thought appropriate, pass the following
resolutions as separate ordinary resolutions:
5(a) Grant of FY27 STI Deferred Equity Rights
“That approval be given for all purposes for the grant
of Deferred Equity Rights to Chief Executive Officer and
Managing Director Mr Jason Martinez under the IDX FY27
Short Term Incentive Plan on the terms set out in the
Explanatory Memorandum."
5(b) Grant of FY27 LTI Performance Rights
“That approval be given for all purposes for the grant of
369,458 Performance Rights to Chief Executive Officer and
Managing Director Mr Jason Martinez under the IDX FY27
Long Term Incentive Plan on the terms set out in the
Explanatory Memorandum.
Note: Voting exclusions apply to this item of business. Please see
page 17 for further details.
- APPROVAL OF EQUITY GRANTS TO DR
IAN KADISH
To consider and, if thought appropriate, pass the following
resolutions as separate ordinary resolutions:
6(a) Pro-rata grant of additional FY26 LTI Performance Rights
To consider and, if thought fit, pass the following resolution as
an ordinary resolution:
“That approval be given for all purposes for the pro-rata grant
of an additional 71,060 Performance Rights to former Chief
Executive Officer and Managing Director Dr Ian Kadish under
the IDX FY26 Long Term Incentive Plan on the terms set out in
the Explanatory Memorandum."
"That Ms Ingrid Player, being eligible, be re-elected as
a Director."
6(b) Pro-rata grant of FY27 LTI Performance Rights
Details of the qualifications and experience of Ms Player are set
out in the Explanatory Memorandum.
“That approval be given for all purposes for the pro-rata
grant of 87,181 Performance Rights to former Chief Executive
Officer and Managing Director Dr Ian Kadish under the IDX
FY27 Long Term Incentive Plan on the terms set out in the
Explanatory Memorandum.
Note: Voting exclusions apply to this item of business. Please see
page 17 for further details.
2026 Notice of Annual General Meeting
03
ITEMS OF BUSINESS
7. APPROVAL OF ISSUE OF SECURITIES UNDER
THE COMPANY'S EQUITY INCENTIVE PLAN
To consider and, if thought appropriate, pass the following
resolution as an ordinary resolution:
“That approval be given for all purposes for issues of securities
under the Company's Equity Incentive Plan on the terms set out
in the Explanatory Memorandum."
Note: Voting exclusions apply to this item of business. Please see
page 17 for further details.
- RENEWAL OF THE PROPORTIONAL
TAKEOVER APPROVAL PROVISIONS IN
THE CONSTITUTION
To consider and, if thought appropriate, pass the following
resolution as a special resolution:
“That pursuant to section 648G of the Corporations Act 2001
(Cth), the existing proportional takeover provisions contained in
rule 6 of the Company's Constitution be renewed for a period of
three years from the date of this meeting.”
By order of the Board
John Merity
Company Secretary
25 September 2026
04
EXPLANATORY MEMORANDUM
This Explanatory Memorandum forms part of the Notice of
Meeting and has been prepared to assist shareholders in
understanding the items of business at the 2026 AGM.
ITEM 1: DISCUSSION OF FINANCIAL
STATEMENTS AND REPORTS
The Company's Annual Report for 2026 (which includes the
Directors’ Report, the Financial Report, the Sustainability Report
and the Auditor’s Reports (collectively the Reports) will be
presented to the AGM.
Neither the Corporations Act nor the Company's Constitution
requires a vote of shareholders on the Reports. However,
shareholders will be given a reasonable opportunity to ask
questions about and make comments on the Reports and the
management of the Company.
Also, a reasonable opportunity will be given to shareholders
to ask the Company's auditor, PwC, questions relevant to the
conduct of the audit, the preparation and content of the Auditor’s
Report on the Financial Report and Sustainability Report, the
accounting policies adopted by the Company in relation to the
preparation of the financial statements and the independence of
the auditor in relation to the conduct of the audit.
Shareholders may also submit questions in advance of the AGM
in accordance with the instructions on page 18 of this notice.
ITEM 2: REMUNERATION REPORT
The Corporations Act requires that at a listed company's
AGM, a resolution that the Remuneration Report be adopted
must be put to shareholders. However, this resolution is
advisory only and does not bind the Directors or the Company.
Nevertheless, the Board will take into account the outcome of
the vote and discussion at the AGM when considering the future
remuneration policies and practices of the Company.
The Remuneration Report sets out the Company's remuneration
arrangements for Directors and Executive Key Management
Personnel of the Company. The Remuneration Report is part of
the 2026 Annual Report and can be found on pages 61 to 83 of
the Annual Report.
Shareholders will have a reasonable opportunity at the
AGM to ask questions about or make comments on the
Remuneration Report.
Voting exclusions apply to this item of business. Please see page
17 for further details.
ITEM 3: RE-ELECTION OF MR TOBY HALL AS
A DIRECTOR
Mr Hall was appointed as an independent Non-Executive
Director of the Company on 28 September 2023 and became
Chair on 29 November 2023. He is also the Chair of the
Nomination Committee and a member of the Audit Committee
and the People, Culture and Remuneration Committee.
Mr Hall has deep healthcare executive leadership experience
in Australia and New Zealand and is an experienced board
and committee chair. From 2014 to 2022, Mr Hall was the
Group CEO of St Vincent’s Health Australia, the second largest
non-government provider of hospital and care services in the
country. He has also overseen multi-site, for-profit generating
businesses at both board and executive levels in employment
services, early learning services and aged care.
Mr Hall also has extensive involvement in policy development
at a federal level in Australia, having served on committees
established by Prime Ministers, Deputy Prime Ministers, Health
Ministers, Employment and Social Services Ministers.
Mr Hall holds a Master of Business Administration degree and is
a Member of the Chartered Institute of Management Accountants
and a Graduate of the Australian Institute of Company Directors.
He is currently a Non-Executive Director of Ingenia Communities
Group (ASX: ING), a director of the Papua New Guinea
Sustainable Development Fund, and a Director of the Indonesia
based Siloam International Hospitals Tbk PT.
Mr Hall is considered by the Board to be an independent
Director.
The Board believes Mr Hall's extensive healthcare leadership
experience, together with his expertise in regulatory policy and
stakeholder management enables him to make a substantial
contribution to the Company and the Board. The Board strongly
supports his re-election and his continued leadership as Chair of
the Board.
Recommendation
The Board (with Mr Hall abstaining) unanimously
recommends that shareholders vote in favour of the reelection of Mr Hall as a Director.
The Chair of the AGM intends to vote all available proxies
in favour of item 3.
Recommendation
The Board unanimously recommends that shareholders
vote in favour of adopting the Remuneration Report.
The Chair of the AGM intends to vote all available proxies
in favour of item 2.
2026 Notice of Annual General Meeting
05
EXPLANATORY MEMORANDUM
ITEM 4: RE-ELECTION OF MS INGRID PLAYER
AS A DIRECTOR
Ms Player was appointed as an independent Non-Executive
Director of the Company on 29 August 2023. She is also
Chair of the Risk, Compliance and Sustainability Committee and
a member of the Audit Committee, the People, Culture and
Remuneration Committee and the Nomination Committee.
Ms Player brings over 20 years experience at senior executive
and board level across healthcare, health technology and
industrial sectors. She has extensive leadership and governance
experience navigating a range of sensitive and complex
commercial, policy and stakeholder issues in highly regulated
industries with large, geographically dispersed workforces.
She is an experienced former Executive and current NonExecutive Director with international commercial and regulatory
experience in mergers and acquisitions, corporate governance,
capital developments, risk and sustainability. During her
executive career she held senior executive roles with
Healthscope Ltd, including the positions of Group Executive –
Legal, Governance and Sustainability, and General Counsel and
Company Secretary.
Ms Player holds a Bachelor of Economics & Bachelor of
Laws (Hons) and is a member of the Australian Institute of
Company Directors.
Ms Player is currently a Non-Executive Director of Cleanaway
Waste Management Limited (ASX: CWY) and Cogstate Limited
(ASX: CGS) and a Director of the Epworth Foundation.
ITEM 5: APPROVAL OF EQUITY GRANTS TO CEO
5(a) Grant of FY27 STI Deferred Equity Rights
5(b) Grant of FY27 LTI Performance Rights
As outlined in the 2026 Remuneration Report, IDX's Executive
Remuneration Framework comprises:
fixed remuneration (delivered as salary and superannuation);
short term incentives under the IDX Short Term Incentive
Plan (STI Plan) (with 50% delivered as cash and 50%
delivered as deferred equity rights vesting after one year
subject to continuous service); and
long term incentives under the IDX Long Term Incentive
plan (LTI Plan) (with 100% delivered as performance rights
vesting after three years subject to performance conditions).
••
•
Shareholders are being asked to approve two separate grants
of equity securities to Mr Jason Martinez, the Chief Executive
Officer and Managing Director:
future deferred equity rights under the FY27 STI Plan (STI
Deferred Equity Rights); and
369,458 performance rights under the FY27 LTI Plan (LTI
Performance Rights).
•
•
The number of STI Deferred Equity Rights to be granted to Mr
Martinez will be determined following the assessment of his
FY27 STI award by the Board after 30 June 2027, but prior to
the 2027 Annual General Meeting. For this reason, the Company
is seeking shareholder approval to grant the FY27 STI Deferred
Equity Rights so that Mr Martinez can receive any STI award for
FY27 at the same time as other executives of the Company.
Ms Player is considered by the Board to be an
independent Director.
Mr Martinez’s current remuneration package comprises:
Remuneration Type
Details
The Board believes Ms Player's extensive legal, risk
management, healthcare and sustainability skills and expertise
are particularly valuable to her contributions as a Board
member and strongly support her re-election.
FY27 Total Fixed
Remuneration (including
superannuation) (TFR)
$750,000
Short term incentive
50% of TFR 'at target' and up
to 100% of TFR 'at stretch'
Long Term Incentive
100% of TFR at maximum
Recommendation
The Board (with Ms Player abstaining) unanimously
recommends that shareholders vote in favour of the reelection of Ms Player as a Director.
The Chair of the AGM intends to vote all available proxies
in favour of item 4.
Under ASX Listing Rule 10.14.1, a listed company must not
issue securities to a director under an employee incentive
scheme unless it obtains the approval of its shareholders. As the
Managing Director of the Company, Mr Martinez is a “director”
for the purposes of Listing Rule 10.14.1.
FY27 STI Deferred Equity Rights
Key terms of the FY27 STI Plan
The aim of the Company’s STI award is to help drive
performance within the Company by providing a STI to reward
executives for the achievement of the Company's performance
goals for the financial year. The Company uses STI Deferred
Equity Rights because they create share price alignment
between Mr Martinez and shareholders and are contingent on
Mr Martinez’s ongoing employment with the Company.
06
Under the STI Plan, Mr Martinez has the ability to earn
50% of FY27 TFR 'at target' and a maximum potential STI
opportunity of up to 100% of TFR 'at stretch'. Mr Martinez’s
entitlement under the FY27 STI award will be determined by
taking into account performance against financial, strategic and
sustainability measures (KPIs) over the period from 1 July 2026
to 30 June 2027.
Final awards under the FY27 STI Plan will be delivered to
participants 50% in cash and 50% in STI Deferred Equity Rights
(intended to be granted in or around September 2027). The
vesting of STI Deferred Equity Rights is subject to Mr Martinez’s
continued employment by the Company for a 12-month period
ending on the trading day after the date of the FY27 results
announcement to the ASX (expected in or around August 2027).
The number of STI Deferred Equity Rights to be issued to Mr
Martinez under the STI Plan cannot be determined until the
end of the 2027 financial year when Mr Martinez's performance
has been assessed against the relevant STI KPIs. However, the
maximum number of STI Deferred Equity Rights which can be
granted will be calculated by dividing 50% of his FY27 STI award
as determined by the Board by the volume weighted average
price of the Company’s shares over the 30 trading days prior
to 30 June 2027, rounded up to the nearest whole number. The
Board retains discretion to award less than the maximum or
no STI at all. The shareholder vote approves only the potential
equity delivery mechanism.
Each STI Deferred Equity Right entitles Mr Martinez to one
ordinary share in the Company on vesting. The Board retains
discretion to make a cash equivalent payment in lieu of an
allocation of shares. Prior to vesting, STI Deferred Equity Rights
do not entitle Mr Martinez to any dividends or voting rights. No
amount is payable by Mr Martinez to take up the STI Deferred
Equity Rights.
Details of Mr Martinez’s performance against the financial,
strategic and sustainability measures of the FY27 STI and the
Board's award under the STI will be disclosed in the FY27
Remuneration Report.
FY27 LTI Performance Rights
Key terms of the FY27 LTI Plan
The Company’s LTI Plan is designed to align the interests of
Mr Martinez with the interests of shareholders by providing him
with the opportunity to receive an equity interest in the Company
through the granting of LTI Performance Rights. The Company
is using performance rights because they create share price
alignment between Mr Martinez and shareholders but do not
provide him with the full benefits of share ownership (such as
dividend and voting rights) unless and until the LTI Performance
Rights vest.
2026 Notice of Annual General Meeting
It is proposed that Mr Martinez be granted 369,458 FY27
LTI Performance Rights. The number to be granted has been
calculated by dividing Mr Martinez’s FY27 LTI opportunity (being
100% of his FY27 TFR) by the volume weighted average price of
the Company’s shares over the 30 trading days prior to 30 June
2026 (being $2.03), rounded up to the nearest whole number.
As the LTI Performance Rights will form part of Mr Martinez’s
remuneration, they will be granted at no cost and there will be
no amount payable on vesting.
Each LTI Performance Right entitles Mr Martinez to one ordinary
share in the Company on vesting. The Board retains discretion
to make a cash equivalent payment in lieu of an allocation of
shares. Prior to vesting, LTI Performance Rights do not entitle
Mr Martinez to any dividends or voting rights.
Performance measures for the FY27 LTI Performance Rights
Mr Martinez’s LTI Performance Rights will be eligible
to vest subject to assessment against the following
performance measures:
aggregate earnings per share (EPS) (50% weighting); and
relative total shareholder return (TSR) (50% weighting).
•
•
Each of these performance measures will be separately
assessed over the three-year period from 1 July 2026 to 30 June
2029 (LTI Performance Period).
Aggregate EPS performance condition
EPS measures the earnings generated by the Company
attributable to each share on issue on a fully diluted basis.
The aggregate EPS performance condition will be measured by
reference to the cumulative Company EPS over the three-year
LTI Performance Period.
The EPS performance condition was selected because of its
correlation with long-term shareholder return and its lower
susceptibility to short-term share price volatility.
The percentage of LTI Performance Rights subject to the EPS
performance measures that will be eligible for vesting (if any)
will be determined as follows:
Aggregate EPS over
three years
% of LTI Performance Rights
that vest
Less than 37.5cps
Nil
Equal to 37.5cps
20%
Between 37.5cps and 47.5cps
Straight line pro rata vesting
between 20% and 100%
Equal to, or above, 47.5cps
100%
Relative TSR performance measures
TSR measures the growth in the Company’s share price
together with the value of any cash dividends and any other
shareholder benefits paid during the LTI Performance Period
(and assuming those dividends were reinvested in additional
shares in the Company).
07
EXPLANATORY MEMORANDUM
Relative TSR provides a direct link between executive
remuneration and shareholder return relative to the Company’s
peers. In respect of the LTI Performance Rights, the Company
has determined that the relevant peer group to measure the
Company’s TSR against is the S&P/ASX300 Accumulation Index,
excluding Banks1 and Resource companies. The Board has
determined that this is most appropriate comparator group for
the FY27 LTI grant given the Company’s market capitalisation
and industry.
The percentage of LTI Performance Rights subject to the Relative
TSR performance condition that will be eligible for vesting (if
any) will be determined as follows:
Relative TSR over three years
% of LTI Performance Rights
that vest
Below the 51st percentile
Nil
51st percentile
50%
Greater than 51st and less
than 75th percentile
Straight line pro rata vesting
between 50% and 100%
75th percentile and above
100%
Testing of the performance measures
The performance measures will be tested at the end of the LTI
Performance Period. Calculation of the performance measures
and outcomes will be determined by the Board in its absolute
discretion, having regard to any matters that it considers
relevant to ensure that the results are appropriate.
The Board also has discretion to amend, waive or replace any of
the terms of the LTI Performance Rights, including as a result
of a corporate action or capital reconstruction or where vesting
conditions are no longer appropriate (e.g. following a significant
unexpected event or circumstances), to address any material
advantage or disadvantage to the holder relative to the position
reasonably anticipated at the time of the grant.
The number of LTI Performance Rights that vest (if any) will be
determined by the Board following completion of testing. Any
remaining portion of the LTI Performance Rights that do not vest
will lapse. If the performance measures are determined to be
satisfied, the LTI Performance Rights will automatically vest by
reference to the vesting schedules above (subject to the malus
and clawback provisions).
Key terms of the Integral Diagnostics Equity Incentive Plan
The LTI Performance Rights and STI Deferred Equity Rights will
be granted under and subject to the terms of the Company's
Equity Incentive Plan. The key terms of the Equity Incentive Plan
are detailed in Item 7 of the Explanatory Memorandum.
Additional information provided in accordance with the ASX
Listing Rules
No STI Deferred Equity Rights or LTI Performance Rights have
been previously granted to Mr Martinez under the Plan.
Mr Martinez is the only Director entitled to participate in, and
receive, LTI Performance Rights and STI Deferred Equity Rights
under the Plan.
If shareholder approval is obtained, the LTI Performance Rights
will be granted within 7 days of the AGM and the STI Deferred
Equity Rights may be awarded in or around September 2027.
No loan will be made by the Company in relation to the
acquisition of the LTI Performance Rights or STI Deferred Equity
Rights or allocation to Mr Martinez of any shares on vesting of
the rights.
Details of any awards under the LTI plan or STI Plan or shares
issued under the Plan will be published in the Company’s Annual
Report relating to the period in which they were issued, along
with a statement that approval for the issue was obtained under
ASX Listing Rule 10.14. Any additional persons covered by ASX
Listing Rule 10.14 who become entitled to participate in an issue
of securities under the Plan after the resolution is approved
and who were not named in this Notice of Meeting will not
participate until approval is obtained under that rule unless an
exception under Listing Rule 10.16 applies.
Outcome if shareholder approval is not obtained
If shareholder approval is not obtained for the proposed grant
of STI Deferred Rights and/or LTI Performance Rights, the
relevant grant to the CEO will not proceed. This may impact IDX's
ability to incentivise the CEO, to align his interests with those
of shareholders and to align his remuneration arrangements
with the remuneration arrangements of IDX's other senior
executives. In these circumstances, the Board will need to
consider alternative arrangements to appropriately remunerate
and incentivise Mr Martinez.
Voting exclusions apply to this item of business. Please see page
17 for further details.
Recommendation
The Board (with Mr Martinez abstaining) considers the
CEO’s total remuneration package, including the proposed
grant of STI Deferred Equity Rights and LTI Performance
Rights to be appropriate in all the circumstances. The
Board (with Mr Martinez abstaining) recommends that
shareholders vote in favour of items 5(a) and 5(b).
The Chair of the AGM intends to vote all available proxies
in favour of items 5(a) and 5(b).
Banks are defined as entities included in the official S&P/ASX 300 Banks Index including NAB, Virgin Money Ltd, Judo Capital Holdings Ltd, CBA, ANZ, Westpac, BOQ, Bendigo & Adelaide Bank Ltd
and MyState Ltd
08
ITEM 6: APPROVAL OF EQUITY GRANTS TO DR
IAN KADISH
•
IDX's new Managing Director and CEO, Mr Jason Martinez was
appointed on 10 November 2025 but was unable to commence
in the role until 6 August 2026. In these circumstances, and at
the request of the Board, Dr Kadish agreed to extend his term as
Managing Director and CEO until Mr Martinez’s commencement
as CEO, and then commence a six-month notice period until his
retirement on 15 February 2027.
the number of FY26 LTI Performance Rights previously
granted to Dr Kadish and approved by shareholders at
the 2025 Annual General Meeting was calculated based on
Mr Kadish’s initial retirement date of 30 June 2026. The
proposed grant simply 'tops up' the previous grant of of
rights to reflect Dr Kadish's extended retirement date of
15 February 2027; and
the number of FY27 LTI Performance Rights proposed to
be granted has also been calculated based on Dr Kadish's
period of service as CEO in FY27 and his extended retirement
date of 15 February 2027. Dr Kadish will continue to provide
ongoing services and support to the Board and to Mr
Martinez during his notice period including in relation to
a number of legacy matters in particular, the IQ earn-out
dispute, where the Board regards it as critical to have
access to and contribution from, Dr Kadish. The FY27
LTI Performance Rights recognise this contribution and
maintain Dr Kadish's alignment with shareholder outcomes
through the full three-year performance period until vesting
is determined.
As consideration for Dr Kadish agreeing to extend his term as
CEO and delay his retirement as set out above, the Board agreed
to seek shareholder approval for the issue to Dr Kadish of
additional LTI Performance Rights to reflect his extended period
of service.
Under ASX Listing Rule 10.11.1, a listed company must not issue
securities to a 'related party' unless it obtains the approval of its
shareholders. Dr Kadish is a 'related party' for the purposes of
Listing Rule 10.11.1 as he was the Company’s Managing Director
within six months of the date of the AGM.
Shareholders are being asked to approve two separate pro-rata
grants of equity securities to Dr Kadish:
71,060 additional performance rights under the FY26 LTI
Plan (FY26 LTI Performance Rights); and
87,181 performance rights under the FY27 LTI Plan (FY27 LTI
Performance Rights).
Additional FY26 LTI Performance Rights
6(a) Pro-rata grant of additional FY26 LTI Performance Rights
6(b) Pro-rata grant of FY27 LTI Performance Rights
On 6 May 2025, Dr Kadish announced his intention to retire
as Managing Director and Chief Executive Officer of IDX after
nine years. Dr Kadish initially agreed to continue to serve as
Managing Director and CEO until 31 December 2025 thereafter
commencing a six month notice period until his retirement on
30 June 2026.
•
•
The Board considers it appropriate to make the proposed
grants because:
at the request of the Board, Dr Kadish agreed to extend
his employment term as Managing Director and CEO due to
the unforeseen delay in Mr Martinez taking on the role. Dr
Kadish was under no obligation to agree to the extension and
his willingness to do so has ensured continuity of leadership
for the Company;
the grants are consistent with IDX's Executive Remuneration
Framework, under which Dr Kadish is eligible to participate
in both the FY26 and FY27 LTI Plans for the period of
his employment;
the FY26 and FY27 LTI Performance Rights proposed to
be granted to Dr Kadish will have the same performance
measures, the same three-year performance period and
the same terms as rights granted to other FY26 and FY27
LTI participants;
performance rights align the interests of Dr Kadish with
the interests of shareholders because the rights proposed
to be granted to Dr Kadish will only vest on the Company
achieving ambitious earnings per share and relative total
shareholder return metrics;
•
•
•
•
At the 2025 Annual General Meeting, shareholders approved the
grant of 114,668 FY26 LTI Performance Rights1 to Dr Kadish. This
represented one third of his FY26 LTI entitlement, being the
pro-rata amount for the period to Dr Kadish’s initial retirement
date of 30 June 2026 within the three year FY26 LTI performance
period of 1 July 2025 to 30 June 2028.
It is proposed to grant Dr Kadish an additional 71,060 FY26
LTI Performance Rights, being the pro-rata allocation for the
additional 8 month period of service to Dr Kadish’s new
retirement date of 15 February 2027. The number to be granted
has been calculated using the same FY26 LTI opportunity for
Dr Kadish and the same IDX share price used for the FY26
LTI calculation2.
The additional FY26 LTI Performance Rights will be granted on
the same terms, including the same performance measures and
performance period as the LTI Performance Rights approved by
shareholders at the 2025 Annual General Meeting. Details of
the FY26 LTI performance conditions were included in the 2025
Notice of Annual General Meeting.
•
2026 Notice of Annual General Meeting
09
EXPLANATORY MEMORANDUM
FY27 LTI Performance Rights
It is proposed that Dr Kadish be granted 87,181 FY27 LTI
Performance Rights. This number has been calculated by
dividing Dr Kadish's FY27 LTI opportunity (being 100% of his
FY27 total fixed remuneration which was unchanged from FY26)
by the volume weighted average price of the Company’s shares
over the 30 trading days prior to 30 June 2026 (being $2.03), and
pro-rating that amount for the period of Dr Kadish's employment
in FY27 over the three year FY27 LTI performance period of
1 July 2026 to 30 June 2029, rounded up to the nearest
whole number3.
The FY27 LTI Performance Rights will be granted with the same
performance measures, the same performance period of 1 July
2026 to 30 June 2029, and otherwise on the same terms as
the FY27 LTI Performance Rights offered to other executives
of the Company. The performance measures for the FY27 LTI
Performance Rights are detailed in Item 5.
Testing of the performance measures
The performance measures for the FY26 and FY27 LTI
Performance Rights will be tested at the end of the
respective three-year LTI performance periods. Calculation of
the performance measures and outcomes will be determined
by the Board in its absolute discretion, having regard to any
matters that it considers relevant to ensure that the results
are appropriate.
The Board also has discretion to amend, waive or replace any of
the terms of the LTI Performance Rights, including as a result
of a corporate action or capital reconstruction or where vesting
conditions are no longer appropriate (e.g. following a significant
unexpected event or circumstances), to address any material
advantage or disadvantage to the holder relative to the position
reasonably anticipated at the time of the grant.
The number of LTI Performance Rights that vest (if any) will
be determined by the Board following completion of testing.
Any award will be delivered in cash following the end of the
relevant performance period. Any remaining portion of the LTI
Performance Rights that do not vest will lapse.
Key terms of the Integral Diagnostics Equity Incentive Plan
The LTI Performance Rights will be granted under and subject
to the Company's Equity Incentive Plan. The key terms of
the Equity Incentive Plan are detailed in Item 7 of the
Explanatory Memorandum.
Additional information provided in accordance with the ASX
Listing Rules
The LTI Performance Rights will be granted at no cost and there
will be no amount payable by Dr Kadish on vesting.
Voting exclusions apply to this item of business. Please see page
17 for further details.
Recommendation
The Board considers the proposed grant of FY26 and FY27
LTI Performance Rights to Dr Kadish to be appropriate
in all the circumstances. The Board recommends that
shareholders vote in favour of items 6(a) and 6(b).
The Chair of the AGM intends to vote all available proxies
in favour of items 6(a) and 6(b).
ITEM 7: APPROVAL OF ISSUE OF
SECURITIES UNDER THE COMPANY'S EQUITY
INCENTIVE PLAN
In 2017, the Company established the Equity Incentive Plan
(Plan) and at the 2017 AGM shareholders approved the issue
of securities under the Plan for a period of three years. At the
2020 and 2023 Annual General Meetings, shareholders approved
renewal of the Company’s ability to issue securities under the
Plan for a further three years.
The Plan is designed to align the interests of eligible employees
with the interests of shareholders by providing the opportunity
for participants in the Plan to receive an equity interest in the
Company through the granting of incentive securities subject to
the satisfaction of performance measures and conditions and the
terms of the Plan.
Shareholder approval for the issue of any securities under
the Plan is being sought so that the securities granted or
issued by the Company under the Plan do not count towards
the Company’s 15% annual limit on issuing securities without
shareholder approval for the next three years.
ASX Listing Rule 7.1 prohibits an entity from issuing more than
15% of its securities in any 12 month period, without obtaining
shareholder approval (unless an exception applies).
ASX Listing Rule 7.2, Exception 13, provides that an issue of
securities under an employee incentive scheme will not count
towards the 15% placement capacity if, within 3 years before the
date of the issue, holders of ordinary securities have approved
the issue of securities under the scheme as an exception to ASX
Listing Rule 7.1.
If shareholder approval is obtained, the LTI Performance Rights
will be granted as soon as practical after the AGM, and in any
event within one month after the AGM.
1.
Dr Kadish's FY26 LTI opportunity was 100% of his FY26 fixed remuneration being $846,248. The number of LTI Rights granted to Dr Kadish was calculated by dividing Dr Kadish’s LTI opportunity by
the volume weighted average share price of the Company’s shares traded on the ASX over the 30 days up to and including 30 June 2025 (being $2.46) and dividing that total number by three to
reflect the pro-rating of his FY26 LTI award to 30 June 2026.
FY26 LTI opportunity of $842,248/$2.46/(594 days of employment out of a performance period of 1,095 days) less 114,668 FY26 LTI Performance Rights already granted.
FY27 LTI opportunity of $842,248/$2.03/(229 days of employment out of a performance period of 1,095 days).
10
Approval is being sought for a further three years, at which time
it must be renewed, or it will expire. If this resolution is not
passed, issues of securities under the Plan may still be made
but must fall within the 15% placement capacity at the time of
issue. The last approval of the issue of securities under the Plan
was on 29 November 2023.
The terms and conditions of the Plan are summarised
as follows:
Offers under the Plan and eligibility
Under the Plan, the Board may invite eligible employees (being
an employee of the Integral Diagnostics Group (including a
director employed in an executive capacity) or any other person
who is declared by the Board to be eligible to receive a grant
of incentive securities under the Plan) to participate in a grant
of incentive securities, which may comprise restricted shares,
performance rights and/or options (Incentive Securities). Offers
will be made to eligible employees on the terms set out in the
Plan and on any additional terms as the Board determines.
Vesting and exercise
Restricted shares, options and/or performance rights granted
under the Plan will vest, and in the case of options, become
exercisable, where any performance measures and any other
relevant measures advised to the participant by the Board have
been satisfied.
On vesting of a performance right or following the exercise of
an option (as the case may be), the Board will allocate the
number of shares in respect of which the performance rights
have vested, or the options have been exercised. Any shares
issued under the Plan will rank equally in all respects with other
shares on issue at that time (except as regards to any rights
attaching to such shares by reference to a record date prior to
the date of their issue). The Board has discretion to determine
that the Vesting of a right or an option will be satisfied by
the Company making a cash payment in lieu of an allocation
of shares for the equivalent value of the performance right
or option.
Cessation of employment
Where a participant ceases to be an employee of the Group,
the Board may determine (in its absolute discretion) that some
or all of a participant’s unvested Incentive Securities lapse,
vest, are forfeited, are exercisable for a prescribed period (if
applicable), or are no longer subject to some of the restrictions
that previously applied. Alternatively, the Board may specify
in any offer to the participant how the participant’s Incentive
Securities are to be treated on cessation of employment.
2026 Notice of Annual General Meeting
Change of control
In the event of a takeover bid, transaction, event or state
of affairs that, in the Board’s opinion, is likely to result in
a change of control of the Company, the Board may, in its
absolute discretion, determine that all or a specified number of
a participant’s Incentive Securities vest or cease to be subject to
restrictions (as applicable).
In the event of an actual change in the control of the Company
then, unless the Board determines otherwise, a pro rata portion
of all unvested Incentive Securities will immediately vest or
cease to be subject to restrictions (as applicable) based on the
portion of the vesting period that has elapsed.
If only some of a participant’s unvested Incentive Securities
will vest in the above instances, all Incentive Securities that
remain unvested will lapse, unless the Board determines a
different treatment.
Alternatively, the Board may specify in any offer to the
participant how the participant’s Incentive Securities are to be
treated on a change of control of the Company.
Corporate actions/reconstructions
In accordance with the terms of the Plan, prior to the allocation
of shares to a participant upon vesting of performance rights
or exercise of options (as the case may be), the Board may
make any adjustments it considers appropriate to the terms
of a performance right and/or option granted to a participant
in order to minimise or eliminate any material advantage or
disadvantage to a participant resulting from a corporate action
or capital reconstruction.
Amendments
The Board may amend the terms of the Plan, or any Incentives
issued under the Plan, including amending, waiving or replacing
any vesting conditions attached to any Incentive Securities
issued under the Plan, if the Board considers those vesting
conditions are no longer appropriate or applicable provided that
the interests of the holder are not, in the opinion of the Board,
materially prejudiced or advantaged relative to the position
reasonably anticipated at the time of the grant.
Dealings in Incentive Securities
Subject to the Company’s Securities Dealing Policy, any dealing
in respect of an Incentive Security is prohibited unless the Board
determines otherwise or the dealing is required by law.
Clawback and malus provisions
If, in the opinion of the Board, a participant’s Incentive Securities
vest or may vest as a result of the fraud, dishonesty or
breach of duties or obligations of any other person, the Board
may determine that Incentive Securities held on behalf of the
participant will lapse or be forfeited, and/or that the participant
must pay or repay as a debt proceeds from shares allocated to
the participant under the Plan.
11
EXPLANATORY MEMORANDUM
Administration of the Plan
The Plan is administered by the Board which has the power
to determine appropriate procedures for administration of the
Plan including to implement an employee share trust for
the purposes of delivering and holding shares on behalf of
participants upon the grant or exercise of Incentive Securities
(as applicable), and may delegate their power arising under
the Plan.
Other Information
The following Incentive Securities have been granted to eligible
employees under the Plan since the last approval of the issue of
securities under Plan (for the purpose of ASX Listing Rule 7.2) in
November 2023:
Year
STI Deferred
Equity Rights and
other STI rights
LTI Performance
Rights
2023
150,427
729,476
2024
256,555
971,382
2025
1
853,036
943,545
2026
224,8002
1,530,3603
Total
1,484,818
4,174,763
- Includes STI incentives granted to the former CEO of Capitol Health agreed as part of the
merger in December 2024 and incentives granted to IDX executives under the Capitol Merger
Performance Incentive.
- STI Deferred Equity Rights approved by the Board but not granted as at the date of this Notice.
- LTI Performance Rights approved by the Board but not granted as at the date of this
Notice. Note that proposed grants to Mr Jason Martinez and Dr Ian Kadish remain subject
shareholder approval.
ITEM 8. RENEWAL OF THE PROPORTIONAL
TAKEOVER APPROVAL PROVISIONS IN
THE CONSTITUTION
The Corporations Act permits a company to include in its
constitution provisions that prohibit the registration of transfers
of shares acquired under a proportional or partial takeover bid
unless a resolution is passed by shareholders approving the
bid. In effect, the approval of Item 8 will enable the Company to
refuse to register shares acquired under a proportional takeover
bid unless that bid is approved by a majority of shareholders.
Section 648G(1) of the Corporations Act provides that a
company’s proportional takeover approval provisions, unless
sooner omitted from its constitution, cease to apply at the end
of three years from adoption or renewal as appropriate unless
otherwise specified. When the provisions cease to apply the
Company’s constitution is modified by omitting the provisions.
A company may adopt its proportional takeover approval
provisions in the same manner in which a company can modify
its constitution (i.e. by special resolution of shareholders).
The Company’s constitution (including the proportional takeover
provisions set out in rule 6) was adopted on 29 November 2023.
Accordingly, the proportional takeover provisions included in
the Constitution will cease to apply after 29 November 2026
unless renewed by the proposed special resolution. If approved
by shareholders, the proportional takeover approval provisions
will be in exactly the same terms and will have effect for three
years from the date of the AGM.
Grants of STI Deferred Equity Rights and LTI Performance Rights
are limited to the Company's Senior Leadership Team.
The proportional takeover provisions, which are contained in
rule 6 of the Constitution, are designed to assist shareholders to
receive proper value for their shares if a proportional takeover
bid is made for the Company.
The maximum number of Incentive Securities proposed to
be issued under the Plan following shareholder approval
is 15,000,000.
The Corporations Act requires that the following information
be provided to shareholders when they are considering the
inclusion of proportional takeover provisions in a constitution.
Voting exclusions apply to this item of business. Please see page
17 for further details.
Effect
Recommendation
The Board (with Mr Martinez abstaining given he is a
participant in the Plan) unanimously recommends that
shareholders vote in favour of the issue of securities under
the Company’s Equity Incentive Plan.
The Chair of the AGM intends to vote all available proxies
in favour of item 7.
12
A proportional takeover bid is one where an offer is made to
each shareholder for a proportion of that shareholder’s shares
(that is, less than 100%). The specified proportion must be the
same in the case of all shareholders. This means that control of
the Company may pass without shareholders having the chance
to sell all their shares to the bidder and the bidder may take
control of the Company without paying an adequate amount for
gaining control.
The Corporations Act allows a company to provide in its
constitution that if a proportional takeover bid is made
shareholders must vote on whether to accept or reject the
proportional takeover bid and that decision will be binding
on all shareholders. This provision allows shareholders to
decide collectively whether a proportional takeover bid is
acceptable in principle and it may ensure that any partial offer is
appropriately priced.
The provisions set out in the Company’s Constitution state that,
in the event of a proportional takeover bid being made, the
Directors must hold a meeting of the shareholders entitled to
vote for the purpose of considering and, if thought fit, passing a
resolution to approve the proportional takeover bid. A resolution
approving the bid must be voted on by the 14th day before the
last day of the bid period, during which the offers under the
proportional takeover bid remain open, or a later day allowed
by the Australian Securities and Investments Commission. The
resolution will be passed if more than 50% of votes are cast in
favour of the approval. The bidder and its associates are not
allowed to vote on the resolution.
If no such resolution is voted on at least 14 days before the last
day of the takeover bid period, the resolution will be deemed to
have been approved. This effectively means that shareholders
may only prohibit a proportional takeover bid by passing a
resolution rejecting the proportional takeover bid.
If the resolution is approved or deemed to have been approved,
a transfer of IDX shares under the proportional takeover bid may
be registered provided it complies with the other provisions of
the Corporations Act and the Constitution.
If the resolution is rejected, the registration of any transfer of
shares resulting from the proportional takeover bid is prohibited
and the proportional takeover bid is deemed by the Corporations
Act to have been withdrawn.
The Directors will breach the Corporations Act if they fail to
ensure the resolution is voted on. If no resolution is voted on by
the deadline, the bid is taken to have been approved.
The proportional takeover approval provisions do not apply to
full takeover bids. The renewed provisions will expire after
three years, unless again renewed by shareholders by a
special resolution. Similar provisions are commonly found in the
constitutions of publicly-listed companies on the ASX and are
regularly renewed.
Reasons for proposing the resolution
Part 6.5 Subdivision 5C of the Corporations Act permits the
inclusion and renewal of proportional takeover provisions in
the Constitution.
The Directors consider that shareholders should continue to
have the opportunity to vote on a proposed proportional
takeover bid.
2026 Notice of Annual General Meeting
If the proportional takeover approval provision is not in the
Constitution, a proportional takeover bid may enable control
of the Company to pass without shareholders having the
opportunity to sell all of their shares to the bidder. Shareholders
may therefore be exposed to the risk of being left as a minority
in the Company and the risk of the bidder being able to acquire
control of the Company without payment of an adequate control
premium for their shares.
The proportional takeover approval provisions decrease this
risk because they allow shareholders to decide whether a
proportional takeover bid is acceptable and should be permitted
to proceed.
No knowledge of any acquisition proposals
At the date of this Notice, no Director of the Company is aware of
any proposal by any person to acquire, or to increase the extent
of, a substantial interest in the Company.
Review of proportional takeover provisions
While proportional takeover approval provisions have been in
effect under the Company’s Constitution, an unsuccessful offmarket takeover bid was made for the Company in November
2017. This takeover bid did not activate the proportional
takeover provisions available in the Constitution as they were
not relevant to the bid.
Accordingly, there are no actual examples against which
to assess the advantages or disadvantages of the existing
proportional takeover approval provisions (that is, rule 6 of the
existing Constitution) for the Directors and shareholders of the
Company. The Directors are not aware of any potential takeover
bid that was discouraged by rule 6.
Potential advantages and disadvantages
The Directors of the Company consider that the proposed
renewal of the proportional takeover provisions has no potential
advantages or disadvantages for Directors because they remain
free to make a recommendation on whether a proportional
takeover bid should be accepted.
The potential advantages of the proportional takeover provisions
for shareholders of the Company are:
shareholders have the right to decide by majority vote
whether a proportional takeover bid should proceed;
the provisions may assist shareholders to avoid being locked
in as a minority;
the bargaining power of shareholders is increased and
this may assist in ensuring that any proportional bid is
adequately priced; and
knowing the view of the majority of shareholders assists
each individual shareholder in assessing the likely outcome
of the proportional takeover bid and whether to approve or
reject that offer.
•
•
•
•
13
EXPLANATORY MEMORANDUM
Some potential disadvantages of the proportional takeover
provisions for shareholders of the Company are:
the provisions are a hurdle to, and may discourage,
the making of proportional takeover bids in respect of
the Company;
shareholders may lose an opportunity of selling some of
their shares at a premium; and
the chance of a proportional takeover bid being successful
may be reduced.
•
•
•
The Board considers that the potential advantages
for shareholders of the proportional takeover approval
provisions outweigh the potential disadvantages. In particular,
shareholders as a whole are able to decide whether or not a
proportional takeover bid is successful.
Recommendation
The Board unanimously recommends that shareholders
vote in favour of renewing the existing proportional
takeover provisions contained in rule 6 of the
Company's Constitution.
The Chair of the AGM intends to vote all available proxies
in favour of item 8.
14
IMPORTANT INFORMATION
ANNUAL REPORT
TECHNICAL DIFFICULTIES
The Company's 2026 Annual Report is available at:
www.integraldiagnostics.com.au/reports/
Technical difficulties may arise during the course of the AGM for
those participating using the Computershare Meeting Platform.
The Chair of the Meeting has discretion as to whether and
how the Meeting should proceed in the event that a technical
difficulty arises. In exercising their discretion, the Chair of
the Meeting will have regard to the number of shareholders
impacted and the extent to which participation in the business
of the Meeting is affected. Where they consider it appropriate,
the Chair of the Meeting may continue to hold the Meeting
and transact business, including conducting a poll and voting
in accordance with valid proxy instructions.
SHAREHOLDERS ENTITLED TO VOTE
For the purposes of the AGM, shares will be taken to be held by
the persons who are registered as shareholders as at 7.00pm
(Melbourne time) on Tuesday, 27 October 2026. Accordingly,
transactions registered after that time will be disregarded in
determining shareholders entitled to vote at the AGM.
PARTICIPATING IN PERSON
Registration for the AGM will open at 9.00am (Melbourne time)
on Thursday, 29 October 2026.
Shareholders should monitor the Company’s website and ASX
announcements where updates will be provided if it becomes
necessary or appropriate to make alternative arrangements for
the holding or conduct of the AGM.
PARTICIPATING IN THE MEETING USING THE
ONLINE PLATFORM
Shareholders and proxyholders who are unable to attend the
AGM in person may participate in the AGM online using the
Computershare Meeting Platform.
By participating in the Meeting using the online platform you will
be able to:
hear the Meeting discussion and view the presentations;
ask questions orally and in writing while the Meeting is in
progress; and
vote in real time during the Meeting.
••
•
Shareholders and proxyholders who wish to participate in the
AGM online via the Computershare Meeting Platform may do
so at http://meetnow.global/MP47PKC. Online registration will
open one hour before the Meeting starts.
To make the registration process for the Computershare Meeting
Platform quicker, shareholders should have their SRN/HIN and
registered postcode or country code ready. Proxyholders will
need to contact the Company's share registrar, Computershare
Investors Services on +61 3 9415 4024 one hour prior to the
meeting to obtain their login details.
On opening the Computershare Meeting Platform:
Click on ‘Join Meeting Now’; and
Shareholders in Australia should enter their SRN/HIN and
postcode registered to the holding. Overseas shareholders
should select the country of the registered holding from the
drop-down list.
••
For this reason, shareholders are encouraged to lodge a
directed proxy by 10.00am (Melbourne time) on Tuesday,
27 October 2026, to ensure that their votes are counted.
VOTING
Each of the resolutions set out in this Notice of Meeting will be
decided by way of a poll. You may vote at the AGM in one of
two ways:
live and at the Meeting in person or online using the
Computershare Meeting Platform, or by proxy, attorney, or
representative; or
in advance of the Meeting, by appointing a proxy, directing
your proxy how to vote, and returning the proxy form by
10.00am (Melbourne time) on Tuesday, 27 October 2026.
•
•
If you have appointed a proxy to attend the Meeting and then
you also attend the Meeting (in person or online) your proxy will
not be revoked, however if you vote on one or more items of
business, your proxy will not be eligible to vote on those items
of business.
The Chair of the Meeting will open the poll at the beginning of
the Meeting and the poll will remain open until the Chair of the
Meeting announces that the poll is closed.
Subject to the voting exclusions, every shareholder has one vote
for each share held.
REQUIRED MAJORITY FOR RESOLUTIONS
Items 2 to 7 of business are ordinary resolutions, meaning the
resolutions must be passed by more than 50% of all votes cast
by shareholders entitled to vote on the resolution (whether in
person or by proxy, attorney, or representative).
Item 8 is a special resolution and must be passed by more
than 75% of all votes cast by shareholders entitled to vote
on the resolution (whether in person or by proxy, attorney
or representative).